ArticleBMC cardiovascular disorders2026
Risk stratification of 1-year atrial tachyarrhythmia recurrence after ablation in patients with persistent atrial fibrillation: ALADS-AF score.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is the most common atrial arrhythmia with high prevalence, low awareness, and low treatment rate in China. Catheter ablation (CA) is an effective treatment, but recurrence remains common in persistent AF (PsAF). The present study aimed to develop a tool for 1-year atrial tachyarrhythmia (ATa) recurrence risk stratification after de novo CA.
methodsThis multicenter, retrospective study collected data from four Chinese hospitals between January 2015 and May 2021. Eligible patients were randomly divided in a 2:1 ratio to development (DC) and test cohorts (TC). One-year ATa recurrence status was primarily obtained from existing medical records. Candidate risk factors for recurrence were initially identified through literature review and investigator consensus. Univariable and multivariable Cox regression analyses were performed to develop the model. The model's discrimination and calibration were evaluated in both cohorts to assess performance.
resultsA total of 1,689 patients who underwent de novo CA were included, with 1,126 in DC and 563 in TC. The mean age was 60.5 years, 71.9% were male, the mean PsAF duration was 2.6 years, and 26.1% experienced 1-year ATa recurrence within 3-12 months post-ablation. Recurrence was associated with older age, larger Left Atrial Diameter (LAD), longer AF duration, and female sex. The ALADS-AF score (Age, LAD, Duration of AF, Sex) was developed, with scores from 0 to 30 and a C-index of 0.57.
conclusionsThe ALADS-AF score is a simple and user-friendly tool for stratifying the risk of 1-year ATa recurrence in patients with PsAF after de novo CA. It may facilitate pre-procedural discussions, help set realistic expectations regarding rhythm outcomes, and support consistent follow-up planning in patients undergoing ablation for PsAF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.